Beyond HER2 and trastuzumab: heterogeneity, systems biology, and cancer origin research may guide the future for personalized treatment of very early but aggressive breast cancer

dc.contributor.author	Roukos, D. H.	en
dc.date.accessioned	2015-11-24T19:33:08Z
dc.date.available	2015-11-24T19:33:08Z
dc.identifier.issn	1527-7755	-
dc.identifier.uri	https://olympias.lib.uoi.gr/jspui/handle/123456789/23500
dc.rights	Default Licence	-
dc.subject	Antibodies, Monoclonal/*therapeutic use	en
dc.subject	Antibodies, Monoclonal, Humanized	en
dc.subject	Antineoplastic Agents/therapeutic use	en
dc.subject	Breast Neoplasms/drug therapy/enzymology/metabolism/pathology	en
dc.subject	Disease-Free Survival	en
dc.subject	Female	en
dc.subject	Humans	en
dc.subject	Neoplasm Staging	en
dc.subject	Receptor, erbB-2/*antagonists & inhibitors/immunology	en
dc.subject	Receptors, Estrogen/metabolism	en
dc.subject	Receptors, Progesterone/metabolism	en
dc.title	Beyond HER2 and trastuzumab: heterogeneity, systems biology, and cancer origin research may guide the future for personalized treatment of very early but aggressive breast cancer	en
heal.access	campus	-
heal.fullTextAvailability	TRUE	-
heal.identifier.primary	10.1200/JCO.2009.27.7061	-
heal.identifier.secondary	http://www.ncbi.nlm.nih.gov/pubmed/20406920	-
heal.identifier.secondary	http://jco.ascopubs.org/content/28/17/e279.full.pdf	-
heal.journalName	J Clin Oncol	en
heal.journalType	peer-reviewed	-
heal.language	en	-
heal.publicationDate	2010	-
heal.recordProvider	Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής	el
heal.type	journalArticle	-
heal.type.el	Άρθρο Περιοδικού	el
heal.type.en	Journal article	en

Αρχεία

Προβολή: 1 - 1 of 1

Προβολή: 1 - 1 of 1